.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10A_InsulinsAndAnalogues.A10AE30_InsulinDegludecAndLiragl.InsulinDegludecAndLiragl .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10A_InsulinsAndAnalogues.A10AE30_InsulinDegludecAndLiragl.InsulinDegludecAndLiragl| name: | InsulinDegludecAndLiraglutide | |
| ATC code: | A10AE30 | |
| route: | subcutaneous | |
| compartments: | 2 | |
| dosage: | 16 | mg |
| volume of distribution: | 10.0 | L |
| clearance: | 0.03 | L/h |
| other parameters in model implementation | ||
Combination of insulin degludec, an ultra-long-acting basal insulin analogue, and liraglutide, a GLP-1 receptor agonist. Used in the management of type 2 diabetes mellitus to improve glycemic control. Approved by regulatory agencies in many countries under the brand name Xultophy.
Pharmacokinetic parameters estimated for healthy adults based on published single-agent studies and product information. No single-population PK study directly available for the fixed combination product.